Physician Views: Previewing the potential role of Tagrisso as first-line therapy

Ref: Physician Views Desk

The third-generation EGFR tyrosine kinase inhibitor (TKI) Tagrisso is now AstraZeneca's biggest growth driver. Sales in 2017 reached $955 million versus $423 million in the prior year.

The drug is currently approved to treat patients with T790M mutation-positive non-small-cell lung cancer (NSCLC) who have progressed on or after prior EGFR TKI therapy, but AstraZeneca is awaiting approval later this year for use as a first-line therapy with EGFR mutation-positive NSCLC.

Regulatory submissions are based on data from the FLAURA trial, showing median progression-free survival (PFS) of 18.9 months for Tagrisso versus 10.2 months for standard of care; though debate centres on whether this benefit is more clinically meaningful than use of an older TKIs followed by Tagrisso in patients who develop resistance - see ESMO Spotlight: AstraZeneca delivers compelling riposte to MYSTIC setback with PACIFIC, FLAURA data.

To get a better understanding of how prescribers are 'primed' for Tagrisso in this setting, we are snap-polling US and EU5 oncologists with the following questions…

Have you used Tagrisso (osimertinib) 'off label' for the first-line treatment of patients with metastatic EGFR mutation-positive NSCLC?

Yes

No

How aware are you of data from the FLAURA study supporting the potential near-term approval of Tagrisso  in this indication?

Not aware

Slightly aware

Moderately aware

Very aware

Extremely aware

Do you intend to routinely use Tagrisso for the first-line treatment of patients with metastatic EGFR mutation-positive NSCLC if it is approved in this indication?

Need to learn more about clinical data

Never

Rarely

Sometimes

Often

Always

To what extent do you think the future availability of generic current standard-of-care EGFR TKIs will limit adoption of Tagrisso as a first-line therapy / delay its use to second-line patients who develop resistance?

No impact

Marginal impact

Moderate impact

Significant impact

Very significant impact

To what extent will a lack of options in treating patients who develop resistance to Tagrisso as a first-line therapy limit its adoption in this setting?

No impact

Marginal impact

Moderate impact

Significant impact

Very significant impact

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.